Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Desmopressin Stories

2014-04-17 08:28:45

- Three-year commitment of up to 20 million units per year of blood clotting medicines to treat hemophilia patients in developing countries BARCELONA, Spain, April 17, 2014 /PRNewswire/ -- Grifols, S.A. (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) today announced that it will donate up to 20 million units of coagulation therapies in each of the next three (3) years to the World Federation of Hemophilia (WFH). Grifols has been a proud supporter of the WFH and its noble efforts for nearly a...

2014-04-17 08:22:44

Inspirational video is launched on World Hemophilia Day to tell the story of one Canadian's triumph over adversity TORONTO, April 17, 2014 /CNW/ - Attitude makes you a hero; that's why John Schmitke, Vice President and Chairman of the Youth Committee at the Canadian Hemophilia Society, Manitoba Chapter, is working to empower and inspire those with hemophilia by sharing his own positive approach to living with this blood disorder. On World Hemophilia Day (April 17, 2014), John...

2014-04-16 08:32:37

6.9 million people have a bleeding disorder. 75 percent of them don't know it. MONTREAL, April 16, 2014 /PRNewswire/ -- Every year on April 17, World Hemophilia Day is observed around the world to increase awareness of hemophilia and other inherited bleeding disorders. In 2014, World Hemophilia Day's theme will encourage the younger generation of the global bleeding disorders community to "Speak out. Create change." "World Hemophilia Day is part of our critical effort to aid in...

2014-03-24 08:28:01

The Approval of ALPROLIX is First Significant Advance in Hemophilia B Treatment in More Than 17 Years CAMBRIDGE, MA, March 24, 2014 /CNW/ - Biogen Idec (NASDAQ: BIIB) has announced that Health Canada approved ALPROLIX((TM) )[Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. ALPROLIX is the first approved long-acting hemophilia B therapy and...

2014-02-18 04:21:07

- The PROTECT VIII study met its primary efficacy and safety objectives for the treatment of patients with hemophilia A WHIPPANY, N.J., Feb. 18, 2014 /PRNewswire/ -- Bayer HealthCare today announced positive results from the PROTECT VIII trial evaluating the company's investigational long-acting site-specific PEGylated recombinant human factor VIII compound BAY 94-9027. The study met its primary objective of protection from bleeds with fewer infusions. In the study, the...

2013-12-23 16:23:07

PLAINSBORO, N.J., Dec. 23, 2013 /PRNewswire/ -- Novo Nordisk today announced the US Food and Drug Administration (FDA) has approved TRETTEN(®) (Coagulation Factor XIII A-Subunit [Recombinant]) for the routine prophylaxis of bleeding in people with congenital factor XIII (FXIII) A-subunit deficiency, a serious, rare bleeding disorder with limited treatment options. TRETTEN(®) is the only recombinant treatment for congenital FXIII A-subunit deficiency. TRETTEN(®) was proven safe and...

2013-11-13 12:27:00

DEERFIELD, Ill., Nov. 13, 2013 /PRNewswire/ -- Baxter International Inc. today announced it has completed enrollment in its Phase III clinical trial of BAX 855, an investigational extended half-life, recombinant factor VIII (rFVIII) treatment for hemophilia A. The ongoing trial is aimed at assessing the efficacy of the compound in reducing annualized bleed rates (ABR) in both prophylaxis and on-demand treatment schedules, and will also evaluate its safety and pharmacokinetic profile....

2013-10-04 08:24:00

RESEARCH TRIANGLE PARK, N.C., Oct. 4, 2013 /PRNewswire/ -- Grifols Inc., a leading manufacturer of life-saving plasma protein therapies, today announced the launch of the SPIRIT (Study of Plasma-derived factor VIII/VWF in Immune toleRance Induction Therapy) registry for patients with hemophilia A at the National Hemophilia Foundation (NHF) annual meeting in Anaheim, Calif. The SPIRIT registry will enroll U.S. patients with hemophilia A and inhibitors being treated with Grifols'...

2013-10-03 08:30:17

Vial Adapter offers Kogenate® FS patients an additional choice in reconstitution systems WHIPPANY, N.J., Oct. 3, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the company is introducing Kogenate® FS antihemophilic factor (recombinant) with Vial Adapter. Vial Adapter is a reconstitution system designed to offer an additional choice for people with hemophilia A. Today's announcement was made at the National Hemophilia Foundation's annual meeting in Anaheim. "Innovating in order...

2013-07-08 04:21:59

Phase III PROTECT VIII Kids Trial will Evaluate the Pharmacokinetics, Safety and Efficacy of BAY94-9027 for Prophylaxis and Treatment of Bleeding in Previously Treated Children with Severe Hemophilia A WAYNE, N.J., July 8, 2013 /PRNewswire/ -- Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its investigational compound BAY94-9027 for the treatment of hemophilia A in children. The PROTECT VIII (PROphylaxis...